<DOC>
	<DOC>NCT00367276</DOC>
	<brief_summary>The purpose of this study is to evaluate the effects on the quality of life and BMI of new contraceptives.</brief_summary>
	<brief_title>Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.</detailed_description>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Drospirenone and ethinyl estradiol combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives, Oral, Combined</mesh_term>
	<criteria>Female requiring contraceptives. Aged 18 to 35 if a nonsmoker, aged 18 to 30 if a smoker. Regular menstrual cycle (defined as duration of 28 +/ 5 days). No Contraindication for OC use</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Females requiring contraceptives</keyword>
</DOC>